261 related articles for article (PubMed ID: 19236820)
1. Non-occupational postexposure prophylaxis for HIV: a systematic review.
Bryant J; Baxter L; Hird S
Health Technol Assess; 2009 Feb; 13(14):iii, ix-x, 1-60. PubMed ID: 19236820
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HIV.
Pinkerton SD; Holtgrave DR; Bloom FR
AIDS; 1998 Jun; 12(9):1067-78. PubMed ID: 9662204
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.
Rabaud C; Burty C; Grandidier M; Christian B; Penalba C; Béguinot I; Jeanmaire H; May T
Clin Infect Dis; 2005 Jan; 40(2):303-5. PubMed ID: 15655751
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
Pinkerton SD; Holtgrave DR; Pinkerton HJ
Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus.
Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
Arch Intern Med; 2004 Jan; 164(1):46-54. PubMed ID: 14718321
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States.
Pinkerton SD; Martin JN; Roland ME; Katz MH; Coates TJ; Kahn JO
AIDS; 2004 Oct; 18(15):2065-73. PubMed ID: 15577628
[TBL] [Abstract][Full Text] [Related]
7. Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients.
Cai J; Xiao J; Zhang Q
Chin Med J (Engl); 2014; 127(14):2632-6. PubMed ID: 25043080
[TBL] [Abstract][Full Text] [Related]
8. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV.
Schechter M; do Lago RF; Mendelsohn AB; Moreira RI; Moulton LH; Harrison LH;
J Acquir Immune Defic Syndr; 2004 Apr; 35(5):519-25. PubMed ID: 15021317
[TBL] [Abstract][Full Text] [Related]
9. Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.
Thomas R; Galanakis C; Vézina S; Longpré D; Boissonnault M; Huchet E; Charest L; Murphy D; Trottier B; Machouf N
PLoS One; 2015; 10(11):e0142534. PubMed ID: 26559816
[TBL] [Abstract][Full Text] [Related]
10. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.
Luque A; Hulse S; Wang D; Shahzad U; Tanzman E; Antenozzi S; Smith B
Infect Control Hosp Epidemiol; 2007 Jun; 28(6):695-701. PubMed ID: 17520543
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus postexposure prophylaxis for adolescents and children.
Merchant RC; Keshavarz R
Pediatrics; 2001 Aug; 108(2):E38. PubMed ID: 11483848
[TBL] [Abstract][Full Text] [Related]
12. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
Diaz-Brito V; León A; Knobel H; Peraire J; Domingo P; Clotet B; Dalmau D; Cruceta A; Arnaiz JA; Gatell JM; García F;
Antivir Ther; 2012; 17(2):337-46. PubMed ID: 22293542
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure.
Young TN; Arens FJ; Kennedy GE; Laurie JW; Rutherford Gw
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD002835. PubMed ID: 17253483
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
Kahn JO; Martin JN; Roland ME; Bamberger JD; Chesney M; Chambers D; Franses K; Coates TJ; Katz MH
J Infect Dis; 2001 Mar; 183(5):707-14. PubMed ID: 11181146
[TBL] [Abstract][Full Text] [Related]
16. [Post-exposure HIV prevention within and outside the hospital].
Jost J
Ther Umsch; 1998 May; 55(5):289-94. PubMed ID: 9643126
[TBL] [Abstract][Full Text] [Related]
17. Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
Penazzato M; Dominguez K; Cotton M; Barlow-Mosha L; Ford N
Clin Infect Dis; 2015 Jun; 60 Suppl 3():S177-81. PubMed ID: 25972500
[TBL] [Abstract][Full Text] [Related]
18. Proposed recommendations for the management of HIV post-exposure prophylaxis after sexual, injecting drug or other exposures in Europe.
Almeda J; Casabona J; Simon B; Gerard M; Rey D; Puro V; Thomas T;
Euro Surveill; 2004 Jun; 9(6):35-40. PubMed ID: 15223890
[TBL] [Abstract][Full Text] [Related]
19. Seroconversion following nonoccupational postexposure prophylaxis against HIV.
Roland ME; Neilands TB; Krone MR; Katz MH; Franses K; Grant RM; Busch MP; Hecht FM; Shacklett BL; Kahn JO; Bamberger JD; Coates TJ; Chesney MA; Martin JN
Clin Infect Dis; 2005 Nov; 41(10):1507-13. PubMed ID: 16231265
[TBL] [Abstract][Full Text] [Related]
20. High HIV incidence in men who have sex with men attending for postexposure prophylaxis: a service evaluation.
Whitlock G; McCormack C; Fearnley J; McOwan A
Sex Transm Infect; 2017 May; 93(3):214-216. PubMed ID: 27412954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
